Hormonal IUD (Mirena/Kyleena) vs Nurtec ODT: How to Think About Switching

What These Two Drugs Actually Do (They Are Not Competitors)

The single most important thing to understand before comparing these medications: Mirena, Kyleena, and Nurtec ODT do not compete for the same clinical role. One is a locally acting intrauterine progestin device; the other is an oral calcitonin gene-related peptide (CGRP) receptor antagonist. Placing them side by side makes sense only when a woman or her clinician is sorting out which problems she needs treated, or when she is considering stopping one of them for a specific reason.

Mirena (52 mg levonorgestrel, lasting up to 8 years) and Kyleena (19.5 mg levonorgestrel, lasting up to 5 years) release a small daily dose of progestin directly into the uterine cavity. Systemic levonorgestrel absorption from Mirena is roughly 10-20 mcg/day, far below systemic hormonal contraceptive doses, which is why many side effects attributed to pills do not occur with the same frequency at the IUD level.

Rimegepant (Nurtec ODT, 75 mg orally dissolving tablet) blocks the CGRP receptor, interrupting the neurogenic inflammation cascade responsible for migraine pain and associated autonomic symptoms. It is currently the only single molecule approved by the FDA for both acute migraine treatment and preventive migraine therapy, taken every other day for prevention or as needed for acute attacks.

Why Women Ask About These Two Together

Women raise this comparison in a few specific situations. First, a woman may have a Mirena in place for heavy menstrual bleeding (HMB) or contraception and then develops new or worsening migraine and wonders whether her IUD is contributing. Second, a woman on rimegepant for migraine prevention may want long-acting contraception and ask whether the IUD is safe alongside her current medication. Third, perimenopause. Migraine frequency often peaks in perimenopause, and the levonorgestrel IUD is a medically recommended progestin source for endometrial protection during low-dose estrogen perimenopause hormone therapy. These are genuinely overlapping clinical territories for many women.

Levonorgestrel IUDs: What the Evidence Shows for Women

Mirena and Kyleena are among the most thoroughly studied intrauterine devices in gynecology. The primary conditions they address for women at WomanRx are HMB, dysmenorrhea, endometriosis, contraception across the reproductive years, and endometrial protection during perimenopausal systemic estrogen therapy.

Heavy Menstrual Bleeding: The NEJM 2013 Trial

The landmark trial most clinicians cite for Mirena in HMB randomized 571 women to the levonorgestrel intrauterine system or usual medical treatment (including tranexamic acid, norethisterone, and combined oral contraceptives). At 6 months, women using the LNG-IUS had a mean 49% greater reduction in menstrual blood loss score compared with usual medical care, along with statistically significant improvements in quality of life. The IUD group also reported higher satisfaction and lower rates of surgical intervention at 2 years.

This matters for life-stage framing. HMB affects an estimated 1 in 5 women of reproductive age, with rates climbing again in perimenopause as anovulatory cycles become more common. Mirena's 8-year duration means it can bridge a woman from her late 30s or 40s through the menopause transition without repeated procedures.

Endometriosis and Dysmenorrhea

The LNG-IUS reduces endometrial prostaglandin production locally, which translates to measurable dysmenorrhea relief. A Cochrane review of LNG-IUS for endometriosis (2021) found the device reduced pain scores, though evidence quality was moderate, and head-to-head data against surgical treatment remain limited. ACOG Practice Bulletin 114 endorses the LNG-IUS as a non-surgical option for endometriosis management.

Perimenopause: A Specific Role the IUD Fills

This is an area where framing by life stage matters a great deal. The Menopause Society (formerly NAMS) recommends that women using low-dose systemic estrogen for perimenopausal symptoms who have an intact uterus require progestin for endometrial protection. The levonorgestrel IUS is recognized as an effective progestin delivery route in this context, keeping systemic progestin exposure very low while protecting the endometrium. For perimenopausal women who also have HMB or dysmenorrhea, the IUD thus serves multiple roles simultaneously.

Side Effects Specific to Women

Irregular bleeding, particularly spotting in the first 3-6 months, affects the majority of new users. Amenorrhea develops in approximately 20% of Mirena users at 1 year and up to 50% at 5 years. Mood-related concerns come up frequently in women's clinical conversations. Observational data suggest a possible association between hormonal IUDs and depression, though the absolute effect size is small and causality is not established. If you have a history of progestin-sensitive mood changes, that conversation belongs with your clinician before insertion.

Rimegepant (Nurtec ODT): What the Evidence Shows for Women

Migraine is a condition women carry disproportionately. About 17-18% of women versus 6% of men meet diagnostic criteria for migraine, and the hormonal relationship is not subtle: migraine attacks cluster around menstruation, shift during pregnancy, and often accelerate in perimenopause before improving after the final menstrual period.

Acute Treatment Evidence

In the key Phase 3 acute treatment trial, rimegepant 75 mg produced pain freedom at 2 hours in 19.6% of patients vs 12.0% with placebo, and absence of the most bothersome symptom in 35.1% vs 26.9%. These numbers look modest in absolute terms, but CGRP antagonists carry a clean tolerability profile compared with triptans, making them particularly useful for women with cardiovascular contraindications to triptans, triptan non-responders, or women who need to avoid vasoconstrictors.

Preventive Evidence: The Lancet 2021 Trial

The Prevention of Migraine Using the Novel CGRP Antagonist Rimegepant trial (published in The Lancet in 2021) randomized 348 adults to rimegepant 75 mg every other day or placebo over 12 weeks. Rimegepant reduced mean monthly migraine days by approximately 4.3 days from a baseline of roughly 10 days, versus 3.5 days for placebo, a statistically significant difference (p=0.0099). About 49% of participants were classified as responders (50% or greater reduction in migraine days) versus 41% in the placebo group.

The trial population was predominantly female (approximately 85%), which is consistent with migraine epidemiology and gives the data reasonable applicability to women, though hormonal subgroup analyses by menstrual cycle phase or contraceptive status were not reported in the primary paper. This is a genuine evidence gap.

Menstrual Migraine: A Key Women's-Specific Topic

Menstrual migraine, defined as attacks occurring consistently within 2 days before through 3 days after menstruation onset, affects approximately 7-14% of women with migraine. These attacks are typically longer, more severe, and more resistant to acute treatment than non-menstrual attacks. Rimegepant's every-other-day dosing schedule could, in principle, cover the perimenstrual window as a mini-preventive strategy, though this specific protocol has not been formally studied in a dedicated menstrual migraine trial. Any use in that fashion should be discussed explicitly with your clinician.

Hormonal Interactions: Does the IUD Affect Rimegepant or Vice Versa?

Rimegepant is a substrate and mild inhibitor of CYP3A4 and P-glycoprotein. The levonorgestrel released from a Mirena or Kyleena acts locally in the uterus and reaches very low systemic concentrations. No pharmacokinetic drug-drug interaction data exist between LNG-IUS and rimegepant specifically, because the systemic levonorgestrel levels from an IUD are low enough that a meaningful interaction is unlikely. Systemic hormonal contraceptives (pills, patches, rings) are not listed as interactions in the Nurtec prescribing information. Use of both simultaneously does not appear to require dose adjustment based on current data, but the direct study has not been done, and that gap should be acknowledged.

Pregnancy, Lactation, and Contraception: Required Reading

This section covers both medications because pregnancy and lactation status changes everything about risk and appropriateness.

Levonorgestrel IUD in Pregnancy and Lactation

Do not insert a levonorgestrel IUD during a known or suspected pregnancy. If a woman becomes pregnant while the IUD is in situ, the device should be removed as early as possible because the risk of septic abortion, premature delivery, and pregnancy loss increases if it remains. ACOG Practice Bulletin 186 states that if the IUD cannot be removed or the woman chooses to continue the pregnancy, she should be counseled about the risks of second-trimester loss and preterm birth.

Fertility returns rapidly after IUD removal. Unlike depot medroxyprogesterone acetate, there is no prolonged return-to-fertility delay with the levonorgestrel IUS. Most women ovulate within one to two cycles.

During lactation, levonorgestrel IUDs are generally considered compatible. The CDC US Medical Eligibility Criteria for Contraceptive Use (US MEC) classifies LNG-IUS insertion in breastfeeding women as Category 2 (benefits generally outweigh risks) if inserted before 4 weeks postpartum, or Category 1 (no restriction) from 4 weeks onward. Levonorgestrel transfer to breast milk occurs at very low levels and is not considered harmful to the infant.

For postpartum women: if you want an IUD placed, the optimal window is either immediately postpartum (within 10 minutes of placental delivery) or after 4 weeks, as insertion between 10 minutes and 4 weeks carries higher expulsion rates.

Rimegepant (Nurtec ODT) in Pregnancy and Lactation

Rimegepant should be avoided during pregnancy. The FDA label notes that animal reproduction studies at doses approximately 20 times the maximum recommended human dose showed delayed fetal development. There are no adequate and well-controlled studies in pregnant women. CGRP plays a role in placental vascular regulation, raising theoretical concerns about impaired placental perfusion, though the clinical significance in humans is unknown.

If you are planning to conceive, discuss stopping rimegepant before trying. Because it has a half-life of approximately 11 hours, it clears the body within a few days of the last dose.

For lactation: rimegepant is present in rat milk. Human breast milk data are absent. The prescribing information advises considering the developmental and health benefits of breastfeeding alongside the potential infant exposure. Given the lack of data, most clinicians are cautious about rimegepant during breastfeeding and may recommend alternative acute or preventive migraine strategies for that period.

Contraception requirement: Rimegepant does not require a specific contraceptive method in labeling, but given the absence of pregnancy safety data and the potential for fetal harm suggested by animal studies, women who could become pregnant should use reliable contraception while taking rimegepant. This is precisely where the levonorgestrel IUD, if clinically appropriate, serves two purposes at once.

Who This Is Right For (And Who It Is Not): A Life-Stage Guide

Reproductive Years (Roughly Ages 18-40)

The levonorgestrel IUD is well matched to women who want long-acting contraception alongside treatment of HMB, dysmenorrhea, or endometriosis. Rimegepant is appropriate for women with episodic or chronic migraine who need either acute rescue or preventive therapy. A woman in her 30s with both endometriosis-related HMB and menstrual migraine is exactly the person who might be using both simultaneously for entirely different indications.

The LNG-IUD is not right for women with unexplained uterine bleeding, distorted uterine cavities, active pelvic inflammatory disease, or a current or recent gestational trophoblastic disease with elevated hCG. Rimegepant is not the right choice for women who are or may be pregnant, women with severe hepatic impairment, or women who want to minimize polypharmacy and whose migraine frequency is low enough to manage with an as-needed non-CGRP option.

Trying to Conceive

Remove the IUD when you are ready to start trying. Fertility typically returns within one to two cycles. Stop rimegepant before actively trying to conceive given the absence of human pregnancy safety data. Discuss acute migraine management during conception attempts with your neurologist or OB-GYN. Acetaminophen, though modestly effective for migraine, is the most commonly recommended acute agent during the periconception period.

Perimenopause

This is the life stage where the IUD has a genuinely strategic role beyond contraception. As mentioned above, the Menopause Society recognizes the LNG-IUS as a progestin source for endometrial protection during systemic low-dose estrogen therapy in perimenopause. Migraine also tends to worsen during perimenopause. A perimenopausal woman on estradiol therapy who has an LNG-IUS for endometrial protection and rimegepant for migraine prevention is using both medications appropriately and within their licensed indications.

Postmenopause

The IUD is rarely placed postmenopause outside of clinical scenarios where ongoing endometrial protection is needed alongside systemic estrogen. Rimegepant can be used postmenopause for migraine. Migraine typically improves after the final menstrual period in the majority of women, but for those whose migraine persists, the same treatment principles apply.

How Switching Actually Works

"Switching" between these medications is not the right framing because they do not overlap in indication. The more accurate scenarios are:

Scenario 1: Adding rimegepant to an existing IUD. You have a Mirena for HMB or contraception and now develop worsening migraine. Your neurologist or your WomanRx clinician can prescribe rimegepant without removing the IUD. No dose adjustment is needed.

Scenario 2: Stopping the IUD and starting rimegepant for an unrelated reason. You want to come off hormonal contraception and are not concerned about HMB. Removing the IUD has no effect on your migraine therapy. Rimegepant can continue uninterrupted through and after IUD removal.

Scenario 3: Stopping rimegepant because you are planning pregnancy. Discontinue rimegepant. Remove the IUD when you are ready to begin trying. Allow the rimegepant to clear (a few days given the approximately 11-hour half-life). Discuss bridging acute migraine therapy during your conception attempt with your prescriber.

Scenario 4: Perimenopause, adding estrogen therapy. You already have an LNG-IUS. Your clinician prescribes low-dose estradiol. The IUD now also serves as your progestin arm of hormone therapy. If your migraine has worsened during the menopause transition, rimegepant can be added without interacting with either the estradiol or the IUD at clinically meaningful levels.

Dr. Elena Vasquez, OB-GYN and WomanRx editorial board reviewer, notes: "Women in perimenopause are often surprised to learn that the levonorgestrel IUD they placed for heavy bleeding in their 40s is doing double duty as endometrial protection when we add estradiol for hot flashes. That is not an accident. It is one of the most elegant uses of a device we have in women's health, and it does not interfere with whatever migraine therapy they need at the same time."

Evidence Gaps: What We Do Not Know Yet

Women have been underrepresented in CGRP trials by life-stage subgroup. The Lancet 2021 rimegepant prevention trial enrolled a predominantly female population but did not stratify outcomes by menstrual cycle phase, contraceptive use, or menopausal status. We do not know whether perimenopausal women respond differently to rimegepant than women in their 20s. We do not have human pharmacokinetic data on rimegepant in breast milk. We do not have a formal drug-drug interaction study between LNG-IUS and rimegepant.

The LNG-IUD literature is better on life-stage differentiation but has its own gaps. Long-term mood and libido outcomes from contemporary smaller-release devices like Kyleena remain understudied compared to Mirena. Direct comparison of the 52 mg and 19.5 mg devices for endometriosis pain is sparse.

These gaps are worth naming plainly because they affect how much confidence you can have in extrapolated guidance versus directly studied outcomes.

Practical Decision Guide: Questions to Bring to Your Clinician

Before your appointment, it helps to be clear on what you are actually trying to treat. Work through these questions:

1. What is the primary problem: contraception, HMB, dysmenorrhea, migraine prevention, acute migraine rescue, or some combination?
2. Are you currently pregnant, planning pregnancy in the next 6-12 months, or breastfeeding?
3. Have you tried other migraine preventives (topiramate, amitriptyline, beta-blockers, other CGRP-pathway agents like monoclonal antibodies) and why did they not work?
4. Have you tried other HMB or endometriosis treatments before the IUD?
5. Do you have any contraindications to intrauterine devices (uterine anomaly, active PID, history of IUD expulsion)?
6. Are you in perimenopause, and are you currently on or considering systemic estrogen?

Bringing clear answers to these questions lets a clinician match the right tool to the right problem rather than positioning these medications as competitors when they are not.